XOMA Royalty Declares Quarterly Preferred Stock Dividends

Rhea-AI Summary

XOMA Royalty (Nasdaq: XOMA) declared quarterly cash dividends for its preferred securities on March 18, 2026. Series A (Nasdaq: XOMAP) will receive $0.53906 per share; Series B depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share.

Both dividends are payable on or about April 15, 2026 to holders of record at the close of business on April 2, 2026.

Positive

• Fixed preferred dividends specified for Series A and Series B
• Clear payment schedule with pay date April 15, 2026 and record date April 2, 2026

Negative

• Common shareholders excluded—dividends apply only to preferred securities
• No aggregate payout disclosed—total cash obligation to holders is not specified

News Market Reaction – XOMAP

-0.19%

-0.19% Session close to close

In the Mar 19 session, XOMAP declined 0.19%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:

Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.   

Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.  

The preferred dividends will be paid on or about April 15, 2026, to respective holders of record at the close of business on April 2, 2026.  

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.    XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO^® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY^® [coagulation factor IX (recombinant)], DARE to PLAY™ (Sildenafil Cream), and DSUVIA^® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

Investor contact:	Media contact:
Juliane Snowden	Kathy Vincent
XOMA Royalty Corporation	KV Consulting & Management
+1-646-438-9754	+1-310-403-8951
juliane.snowden@xoma.com	kathy@kathyvincent.com

   

FAQ

What dividend did XOMA Royalty (XOMA) declare for Series A preferred on March 18, 2026?

Series A holders will receive $0.53906 per share as the declared cash dividend. According to the company, the dividend is payable on or about April 15, 2026 to holders of record at close of business April 2, 2026.

How much will XOMA Royalty pay per Series B depositary share (XOMAO) in April 2026?

Holders of XOMAO depositary shares will receive $0.52344 per depositary share. According to the company, the payment is scheduled on or about April 15, 2026 to holders of record at April 2, 2026.

When is the record date and payment date for XOMA Royalty preferred dividends declared March 18, 2026?

The record date is April 2, 2026 and the payment date is on or about April 15, 2026. According to the company, dividends will be paid to holders of record at the close of business on April 2, 2026.

Do XOMA common shareholders receive the March 18, 2026 preferred dividend?

No, this dividend applies only to the Series A and Series B preferred securities, not to common stock. According to the company, declared payments target holders of the specified preferred shares and depositary shares.

Where can XOMA Royalty preferred shareholders expect payment for the declared dividends in April 2026?

Preferred shareholders should expect cash payments on or about April 15, 2026. According to the company, payments will be made to holders of record as of the close of business on April 2, 2026.